ArticleJournal of the Canadian Association of Gastroenterology2022

Cost-Effectiveness of Tight Control for Crohn's Disease With Adalimumab-Based Treatment: Economic Evaluation of the CALM Trial From a Canadian Perspective.

Peter L Lakatos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.